Podcast: Download (Duration: 16:10 — 14.8MB) | Embed
The CEO of Cyplasin Biomedical Ltd. (OTCBB: CPBM), Garth Likes, called into SmallCapVoice.com to discuss how Cyplasin stays focused on anti-viral therapies and a preventative vaccine in the Hepatitis C market. The Company is interested in talking to other pharmaceutical and biotechnology companies in an effort to license and partner the other indications derived from this core technology platform. Mr. Likes concludes, “By announcing this first deal related to several cancer targets, we hope to attract other strategic partners with interests in any or all of the potential therapeutic areas where this technology might be applied.”